Pfizer/BioNTech COVID-19 vaccine highly effective six months after second dose

Pfizer/BioNTech COVID-19 vaccine highly effective six months after second dose

The Pfizer/BioNTech COVID-19 vaccine is more than 91 percent effective six months after people get their second dose, according to new test data released by the companies.

The findings from more than 46,000 trial participants was released Thursday, CBS News reported. There were 927 confirmed symptomatic cases of COVID-19 overall, with 850 cases in the and 77 cases among those who received the vaccine.

The companies also announced that the vaccine is safe and effective in children as young as 12 years, and they plan to seek emergency use authorization in the United States and Europe for the vaccine to be given starting at age 12 years, CBS News reported.

That means that children 12 years and older could start receiving the vaccine before going back to school in the fall.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

More information: CBS News Article

Copyright © 2021 HealthDay. All rights reserved.

Citation: Pfizer/BioNTech COVID-19 vaccine highly effective six months after second dose (2021, April 2) retrieved 21 January 2022 from https://medicalxpress.com/news/2021-04-pfizerbiontech-covid-vaccine-highly-effective.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
5 shares

Feedback to editors